The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1409
ISSUE1409
February 4, 2013
Apixaban (Eliquis) - A New Oral Anticoagulant for Atrial Fibrillation
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Apixaban (Eliquis) - A New Oral Anticoagulant for Atrial Fibrillation
February 4, 2013 (Issue: 1409)
The FDA has approved apixaban (Eliquis – Bristol-Myers Squibb/Pfizer), an oral direct factor Xa inhibitor,
for prevention of stroke and systemic embolism in
patients with nonvalvular atrial fibrillation. It is the third
new oral anticoagulant to...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.